Identification of Sites in Domain I of Perlecan That Regulate Heparan Sulfate Synthesis*

  1. Michael Dolan,
  2. Teresa Horchar,
  3. Brian Rigatti and
  4. John R. Hassell
  1. From the Ophthalmology Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Eye & Ear Institute, Pittsburgh, Pennsylvania 15213
  1. To whom correspondence should be addressed:
    Ophthalmology Research Center, Dept. of Ophthalmology, University of Pittsburgh School of Medicine, 203 Lothrop St., Rm. 915, Eye & Ear Institute, Pittsburgh, PA 15213
    .

Abstract

Perlecan is primarily a heparan sulfate containing proteoglycan found in all basement membranes. Rotary shadowed images of perlecan show it to contain three glycosaminoglycan (GAG) side chains extending from one end of its core protein. Domain I is at the N terminus of perlecan and contains three closely spaced Ser-Gly-Asp sequences that may serve in GAG attachment. We evaluated the serines in these three sequences for GAG attachment by preparing a cDNA construct encoding for the N-terminal half (domains I, II, and III) of perlecan and then a series of constructs containing deletions and mutations within domain I of the domain I/II/III construct, expressing these constructs in COS-7 cells, and then analyzing the recombinant product for GAG side chains and GAG type. The results showed that all three serine residues in the Ser-Gly-Asp sequences in domain I can accept both chondroitin and heparan sulfate side chains but that a cluster of acidic residues N-terminal to these sequences is the primary determinant responsible for targeting these sites for heparan sulfate. Furthermore, there are two elements that can enhance heparan sulfate synthesis at a targeted site: 1) the presence of a the SEA module in the C-terminal region of domain I and 2) the presence of multiple acceptors in close proximity. These results indicate that the proportion of heparan and chondroitin sulfate at any one site in domain I of perlecan is regulated by multiple factors.

Footnotes

  • * This work was supported by National Institutes of Health Grant R01 GM45380. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • 1 The abbreviations used are:

    GAG

    glycosaminoglycan

    D I, II, and II, domains I, II, and II

    respectively

    DW

    distilled water

    SEA

    sperm enterokinase agrin.

    • Received April 18, 1996.
    • Revision received October 16, 1996.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement